The price of BCRX is predicted to go up -0.04%, based on the high correlation periods with RS. The similarity of these two price pattern on the periods is 95.94%.
BCRX
RS
Down: -0.04%Similarity: 95.94%
BCRX Revenue Forecast
BCRX EPS Forecast
BCRX FAQs
What is bull’s view on BCRX?
Bulls are optimistic about BCRX due to its strong growth prospects, particularly with Orladeyo's sales momentum and a promising pipeline. Analysts have set price targets ranging from $10 to $18, with JMP Securities reiterating a bullish stance and a $18 target, reflecting confidence in the company's strategic direction and financial health. The stock, currently trading at $7.62, offers significant upside potential based on these targets.
What is bear's view on BCRX?
Bears might argue that BCRX's current price of $7.62 reflects limited upside due to its ongoing net losses, despite revenue growth. Concerns about profitability, which is only expected by FY26, and competition in its niche market could weigh on sentiment. Additionally, the stock's reliance on Orladeyo's success and high valuation relative to earnings potential may deter bearish investors.
What is BCRX revenue forecast for next quarter?
The market consensus for BCRX's revenue in the upcoming quarter is projected to be approximately $126.636M USD.
What is BCRX eps forecast for next quarter?
The market consensus for BCRX's eps in the upcoming quarter is projected to be approximately $0.05 USD.
Barclays raised the firm's price target on BioCryst to $8 from $7 and keeps an Equal Weight rating on the shares post the Q3 report. Orladeyo's Q3 revenue was a modest beat and the company's 2024 revenue guidance was narrowed to the upper end of tee range, the analyst tells investors in a research note.